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ABSTRACT
The solitary fibrous tumour (SFT) is a rare tumour, which usually occurs in the pleura. Patients with an advanced 
SFT have a poor prognosis. The treatment options for recurrent disease are especially limited. We present the 
case of a 55-year-old female patient with a malignant SFT of the pleura, who received conventional chemotherapy 
and targeted therapy. This paper focuses on systemic therapy in the treatment of metastatic SFT.
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Introduction
The solitary fibrous tumour (SFT) is a mesenchy-
mal tumour, which in most cases concerns the pleura 
[1]. These tumours constitute less than 5% of pleural 
tumours and less than 2% of all soft tissue tumours [1]. 
SFT occurs in men and women with similar frequency, 
usually in the sixth and seventh decade of life [1]. 
More than half of the patients present no symptoms, 
and lesions in the lungs are detected incidentally dur-
ing follow-up radiological tests. For the other half of 
the patients, the disease usually manifests itself with 
dyspnoea and chest pain. Solitary fibrous tumours are 
usually well limited, benign lesions. Malignant variants 
with a tendency towards recurrence and metastases oc-
cur significantly less often (10–20%) [1]. An evaluation 
of the tumour’s traits in radiological, pathological, and 
immunohistochemical testing allows for the diagnosis 
of its malignant character. The malignant form of the 
tumour is abundant in cells, with ample polymorphism 
and an increased mitotic activity — a mitotic index above 
four mitoses per large field of view, with the presence of 
widespread necrosis and bleeding. The basic treatment 
method for the SFT is excision [1]. In about 20–30% of 
patients, local recurrence or spreading may occur — in 
such a case there is no local treatment option, and sys-
temic treatment must be considered [2]. Data pertaining 
to systemic treatment are limited; the present work aims 
to review the literature and summarise the knowledge 
on the topic of systemic treatment in solitary fibrous 
tumours of the pleura. 
Case report
In August 2013, a 55-year-old female presented 
at the oncology clinic, with a history of mediastinal 
tumour that was excised and diagnosed as a malignant 
SFT. The patient was in good condition (grade 1 on 
the ECOG scale), presenting no weight loss, and obese 
(weighing 130 kg). She had a history of hypertension. 
Presenting complaints included weakness and sporadic 
cough lasting for several months. Physical examination 
and routine laboratory testing conducted on the day of 
the visit revealed no clinically significant abnormali-
ties. Due to a positive surgical margin (R1), the patient 
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was qualified for radical adjuvant radiation. Intensity 
Modulated Radiation Therapy (IMRT) was applied to 
the right pleural area up to a total dose of 5600 cGy, in 
28 fractions of 200 cGy each. After the completion of 
radiotherapy, the patient remained under observation. 
Two years after the diagnosis, in a control CT scan of 
the thorax, progressive disease (PD) was detected in the 
form of three small tumours of the left lung. A wedge 
resection was performed, with a histopathological con-
firmation of the recurrence of an SFT. Subsequently, 
in January and March of 2016, the patient underwent 
a thoracotomy due to the presence of further lesions in 
the lungs. In a CT of the thorax conducted two months 
after surgery, another recurrence was noted, in the form 
of numerous lesions in the lungs with maximum dimen-
sions of 20 × 15 mm. Due to a lack of radical treatment 
possibilities, after a multi-specialist consultation, the 
patient was qualified for palliative chemotherapy with 
cisplatin (80 mg/m2) in conjugation with doxorubicin 
(40 mg/m2) at 21-day intervals. Four courses of treat-
ment were applied, attaining stable disease (SD). In 
November 2016 imaging showed another instance of 
progressive disease. The patient remained in good 
condition. Tests such as ECG, echocardiography and 
blood biochemistry showed no abnormalities that would 
be contraindications of another course of systemic treat-
ment. Treatment with pazopanib was initiated at a dose 
of 800 mg/day, attaining SD once again. The treatment 
was continued for a year, until progression. In November 
2017, at a multi-specialist session, progressive disease 
was confirmed at level 1.1 according to the RECIST 
criteria (Response Evaluation Criteria in Solid Tu-
mours) — a single metastatic lesion appeared in segment 
IV of the liver. Stereotactic radiotherapy was applied 
(5000 cGy in five fractions at 1000 cGy), and subsequently 
chemotherapy with the use of gemcitabine and docetaxel 
was initiated. After the third treatment cycle, PD was 
found. The chemotherapy was changed to a doxorubicin, 
dacarbazine, and cyclophosphamide regimen. In May of 
2018 PD was noted once more in the thorax and abdo-
men. Another line of chemotherapy using ifosfamide 
showed no effect. The patient remains in good overall 
condition (ECOG-1). The patient complained only of an 
increase in exercise intolerance. Previous treatment was 
conducted with no significant complications. 
Discussion
Singular fibrous tumours are usually well-limited 
benign lesions, with malignant forms occurring signifi-
cantly less often (10–20%) [1]. Benign SFTs of the thorax 
are characterised by a high cure rate, with the rate of 
local recurrence being 8% [1]. The rate of recurrence 
in the case of a malignant SFT reaches 14–68%, usually 
in the first two years of observation (even after radical 
resection) [1, 2]. However, recurrences can also occur 
even after 17 years [3]. Metastases within the thorax are 
detected in 0–36% of patients, and metastases outside of 
the thoracic cavity occur in 0–19% of patients with this 
diagnosis. The most common sites of metastasis are the 
lungs and the liver [1]. Less commonly, it metastasises 
to the mediastinum, pancreas, kidney, and bone [1]. The 
evaluation of the tumour in imaging, and pathological 
and immunohistochemical testing allows for the predic-
tion of its malignant character. There are classifications 
that evaluate not just the histological type (benign/malig-
nant form), but also the type of growth that the tumour 
is presenting (pedunculated vs. wide-based). They were 
proposed as a means of predicting recurrence after 
surgical treatment [1]. The rate of recurrence ranges 
from 2 to 63%, depending on the attributed grade. 
A complete resection of the primary lesion still remains 
the most important prognostic factor [3]. Metastatic or 
locally recurring SFTs may require repeated surgical 
treatment, radiotherapy, or systemic treatment. The 
preferred method of treatment in the case of localised 
lesions is local treatment. Solitary fibrous tumours are 
commonly considered to be neoplasms of low chemo-
therapeutic susceptibility [4]. The present work aims 
at a review of the literature pertaining to the systemic 
treatment of SFTs of the pleura.
Chemotherapy
The role of chemotherapy was evaluated in a ret-
rospective work including a group of 21 patients with 
advanced SFT, unqualified for surgical treatment [4]. 
Most patients were Caucasian (81%), and the aver-
age age was 56 years. The most common sites of the 
primary lesion were the abdomen and pelvis. In 19% 
of patients, the lesions occurred primarily in the pleura 
of lungs. Primarily advanced disease occurred in 81% 
of the patients, and local recurrence affected 5% of pa-
tients. Chemotherapy as the first line of treatment was 
prescribed in 72% of the study participants. 24% of them 
received the second line of treatment, and one patient 
received the third line of chemotherapy. Fifteen patients 
(60%) received doxorubicin-based chemotherapy as 
the first line of treatment. The most commonly applied 
regimen was doxorubicin (75 mg/m2) with ifosfamide 
(10 g/m2). About 7% of the patients received doxoru-
bicin and cisplatin chemotherapy. The other regimens 
and treatment responses are presented in Table 1 [4]. No 
patient attained objective response, no matter the ap-
plied regimen. 89% of the patients who received the first 
line of chemotherapy achieved stable disease, with 31% 
achieving stable disease for longer than six months. After 
the second line of treatment, 67% of patients achieved 
stable disease. Median progression-free survival time 
for the first line of chemotherapy was 4.6 months (95% 
CI 3.7–5.6 months) [4]. In conclusion, the authors point 
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Table 1. Chemotherapy response evaluated according to the RECIST criteria RECIST 1.1 [4]
Chemotherapy regimen SD — N (%) PD — N (%)
First-line treatment
Doxorubicin regimen
Doxorubicin + ifosfamide
Doxorubicin + dacarbazine
Doxorubicin + cisplatin
Doxorubicin in monotherapy 
Gemcitabine regimen
Gemcitabine+ docetaxel
Gemcitabine in monotherapy
Paclitaxel
16 (89%)
14
1
1
2 (11%)
1
1
1
Second-line treatment
Gemcitabine in monotherapy
Paclitaxel in monotherapy 
4 (67%) 2 (33%)
Third-line treatment
Gemcitabine
0 (0%) 1 (100%)
PD — progressive disease; SD — stable disease
Table 2. Choi response criteria 
Choi
CR Disappearance of all target lesions
PR ≥ 10% decrease tumour size or ≥ 15% decrease in tumour attenuation at CT
SD Does not meet criteria for CR, PR, PD
PD ≥ 10% increase in sum of longest diameters of lesions does not meet the criteria for partial response by virtue of 
tumour attenuation, new intratumoural nodules
CR — complete response; PR — partial response; SD — stable disease; PD — progressive disease
out the role of chemotherapy as a therapeutic option 
with patients with locally advanced or metastatic SFT 
enabling disease control. 
Trabectedin is an alkaloid extracted from the sea 
squirt Ecteinascidia turbinata. The substance binds to 
the minor groove of the DNA helix, and its biological 
mechanism of action involves modulating transcription 
factors and interaction with proteins responsible for 
repairing DNA [5]. Trabectedin is a drug registered for 
the treatment of patients with diagnoses of advanced 
soft tissue sarcoma. In Poland, contrary to many other 
EU countries, this drug is reimbursed only for its lipo-
sarcoma and leiomyosarcoma subtypes [5]. In a case 
report of a 39-year-old male diagnosed with advanced 
SFT, trabectedin was used after a failed first-line treat-
ment intervention. The drug was administered at a dose 
of 1.5 mg/m2 in 21-day intervals. After the third course 
of treatment, a decrease in the size of the metastatic 
lesions in the lungs was observed [3]. In a French study 
the treatment effectiveness of trabectedin was evalu-
ated for 11 patients with diagnoses of advanced SFT 
(the second and third line of treatment) [6]. PR was 
achieved with one patient (9.1%) and SD for seven 
patients (72.7%). Median progression-free survival time 
was 11.6 months. Three patients (27.3%) exhibited toxi-
city at level 3 or higher — mainly haematological and 
hepatic toxicity (increased hepatic enzyme activity) [6].
Molecular-guided therapy
Pazopanib is a multi-kinase inhibitor of vascular 
endothelial growth factor receptors, platelet-derived 
growth factor receptors, and stem cell growth factor 
receptor (KIT). The effectiveness of pazopanib in the 
treatment of SFTs in preclinical and clinical trials was 
evaluated by Stacchiotti et al. [7]. In the paper, pazo-
panib showed lower antitumour activity in mouse models 
(in comparison to sorafenib, sunitinib, regorafenib, 
axitinib and bevacizumab). Among the six patients who 
received pazopanib, three achieved SD and three PD 
(as evaluated with RECIST criteria). All PD cases were 
patients with a malignant form of SFT. Evaluating the 
response with Choi criteria (Table 2), one achieved 
partial response, two cases of SD, and three cases of 
PD. Median progression-free survival was three months 
(1–15 months) [7]. The effectiveness of pazopanib in 
treating soft tissue sarcomas (including SFTs) was also 
assessed in the PALETTE analysis [8]. This analysis 
was an international, multicentre, double-blind, pla-
cebo-controlled phase III trial. It compared treatment 
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responses vs. placebo of patients with advanced disease 
after at least one line of chemotherapy. The patients 
were randomly assigned to one of two groups: those 
receiving placebo (n = 123) or those receiving pazopanib 
at a dose of 800 mg once a day (n = 246). All of them had 
undergone anthracycline treatment. Median PFS was 
4.6 months (95% CI 3.7–4.8 months) for pazopanib and 
1.6 months (0.9–1.8) in the placebo group (HR, hazard 
ratio 0.31, 95% CI 0.24–0.40; p < 0.0001). The diff e - 
rences in overall survival were not substantial between 
the groups (p = 0.25) and were: 12.5 months in the pa-
zopanib arm and 10.7 months (median) in the placebo 
arm. 67% of patients who received pazopanib achieved 
SD (38% in the placebo group). The treatment was well 
tolerated. The most commonly reported side effects 
were fatigue (65%), diarrhoea (58%), nausea (54%), 
weight loss (48%), and arterial hypertension (41%) [8]. 
In Poland, because of this research, it is possible to use 
pazopanib to treat advanced (unresectable or meta-
static) sarcomas within the National Health Fund (NFZ) 
drug program. In 2018, a paper evaluating the effective-
ness and safety of pazopanib treatment in patients with 
a diagnosis of recurrent or metastatic SFT as the first or 
second line of treatment was published [9]. The response 
was graded according to RECIST and Choi criteria. The 
responses were, respectively, 0% and 50%, depending 
on the applied response criteria. The percentage of 
patients who achieved disease control was 88.9% and 
75%, respectively. Median PFS was 6.2 months (95% 
CI 3.2–8.8 months). Two patients (22.2%) exhibited 
a level 3 or higher increase in hepatic enzyme activity [9]. 
A different analysis presented the effects of pazopanib 
application in second-line and third-line treatment [10]. 
No objective responses to treatment were observed, and 
SD, being the best response, was observed in three out 
of six treated patients. Two patients receiving had no 
PD after six and eight months [10].
From among molecular-guided drugs, promising 
results were obtained also for sunitinib and figitumumab 
[11]. Sunitinib is a multi-kinase inhibitor of, among oth-
ers, the VEGF receptor. Six treated patients (60%) with 
advanced, chemotherapy-resistant SFT achieved PR 
(Choi criteria). For most of them the response lasted 
for longer than six months [11]. Insulin-like growth fac-
tor-1 (IGF-1) undergoes excessive expression in some 
cases of SFT. Treatments with figitumumab, a human 
monoclonal antibody against the IGF-1 receptor, yields 
promising results [11].
Chemotherapy + molecular-guided therapy
The effectiveness of combining temozolomide with 
bevacizumab (VEGF monoclonal antibody) was evalu-
ated retrospectively for 14 patients with locally advanced 
or metastatic SFT or HPC (haemangiopericytoma) [12]. 
For three patients the disease was primarily localised 
in lungs or pleura. Five patients had received earlier 
chemotherapy. In the work, the patients received temo-
zolomide at a dose of 150 mg/m2 orally on days 1–7 and 
15–21 and bevacizumab at 5 mg/m2 IV on days 8 and 
22 in 28-day cycles. Objective response according to 
Choi criteria was achieved in 11 (79%) patients. Two 
(14%) exhibited SD and one (7%) PD. The response was 
also evaluated using RECIST criteria. This time, most 
patients (12 patients) achieved SD. Median PFS was 
9.67 months (Choi PFS). The most commonly observed 
toxicity was bone marrow suppression [12].
Immunotherapy
In a case report of a 50-year-old patient with a diag-
nosis of malignant form of SFT of the pleura, after many 
lines of systemic treatment (carboplatin + paclitaxel, 
gemcitabine + docetaxel, temozolomide + bevacizum-
ab), treatment with pembrolizumab was introduced [13]. 
The drug was administered in two doses at 2 mg/kg IV 
every three weeks. After two cycles of treatment a partial 
regression of lesions was achieved. The patient is cur-
rently continuing the therapy (the last entry — 31 cycle) 
and is tolerating the treatment very well [13]. 
About 20% of patients with diagnosed SFT experi-
ence local recurrence or distant metastases [12]. The first 
line of treatment should be resection of lesions, which 
is not always possible. Available options for treating 
nonresectable tumours are limited. Radiotherapy can 
only be used in selected cases. Chemotherapy using 
doxorubicin and ifosfamide is used in many subtypes 
of soft tissue sarcomas. Another treatment regimen 
can be a combination of gemcitabine and docetaxel. 
However, objective responses to standard chemotherapy 
treatments are rarely reported [12]. In patients treated 
with first-line anthracyclines we can consider using pa-
zopanib. Promising results can also be found for other 
molecular-guided drugs [11, 12] and immunotherapy 
[13]. However, further research is needed for larger 
groups of patients, which could confirm the effective-
ness of these therapies. The presented patient, after an 
attempt to treat her locally, finally required systemic 
treatment. The applied chemotherapy regimens resulted 
in only short-term disease stabilisation or progression, 
which confirms the low sensitivity of SFTs to this form 
of systemic treatment. Treatment with pazopanib led 
to SD (RECIST criteria 1.1) that was maintained for 
a year. Unfortunately, retrospective evaluation with 
Choi criteria was not possible. Currently, the patient 
is experiencing another PD. She remains under ob-
servation and symptomatic care. We can ask ourselves 
whether the application of consecutive lines of systemic 
treatment was appropriate. We do not have sufficient 
information regarding the effects of chemotherapy on 
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general survival of patients with diagnosed SFT of the 
pleura, and the PALETTE analysis showed that the 
differences in overall survival of patients in both groups 
were statistically insignificant. The presented patient 
tolerated the treatment very well and she remains in 
overall good condition. However, we are unable to 
assess if the applied treatments changed her prognosis 
and whether we should consider the significantly longer 
progression-free time and/or the increase in objective 
response as clinically significant.
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